Onkologie. 2011:5(6):347-349

Multidisciplinary approach in the radical treatment of patients with liver metastases

Miroslav Ryska
Chirurgická klinika 2. LF UK a ÚVN, Praha

of colorectal cancer from the perspective of a surgeon

Radical resection of metastases is currently the most effective treatment modality in patients with liver metastases of colorectal cancer. Conversion

therapy is effective for the patients, whose metastases are not primarily resecable. With this therapy is achieved a downsizing in 25%,

followed by performing liver resection. Large hepatic resection and biochemotherapy is suitable to perform at the specialized department

on which is guaranteed a multidisciplinary approach to treatment. This approach not only guarantees low operating risk and use adequate

(neo)adjuvant therapy, but also the complexity of reaching more than 50 % five year survival with good quality of life. Further improvements

in the lives of patients is subject to an early transition to an individualized approach and personalized approach to treatment.

Keywords: colorectal cancer, liver metastases, multidisciplinary approach, radical treatment

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ryska M. Multidisciplinary approach in the radical treatment of patients with liver metastases. Onkologie. 2011;5(6):347-349.
Download citation

References

  1. Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. J Surg 1995; 19: 59-71. Go to original source... Go to PubMed...
  2. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation and combined resectio/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825. Go to original source... Go to PubMed...
  3. Jaeck D. The significance of hepatic pedicle lymph nodes metastase in surgical management of colorectal liver metastase and of the other liver malignancies. Ann Surg Oncol 2003; 10: 1007-1011. Go to original source... Go to PubMed...
  4. Kaczirek K, Tamandl D, Kliner M, et al. Criteria for resectability of colorectal cancer liver mestatases - an Austrian survey and current recommendations. Eur Surg 2009; 41: 213-220. Go to original source...
  5. Benzoni E, Cojutti A, Lorenzin D, et al. Liver resective surgery: a multivariate analysis of postoperative outcome and complication. Langenbecks Arch Surg 2007; 392: 45-54. Go to original source... Go to PubMed...
  6. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008; 13: 51-64. Go to original source... Go to PubMed...
  7. Haas RJ, Wicherts DA, Adam R. Resection of colorectal liver metastase with extrahepatic disease. Dig Surg 2008; 25: 461-466. Go to original source... Go to PubMed...
  8. de Jong MC, Pulitano C, et al. Rates and patterns of reccurence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1699 patients. Ann Surg 2009; 250: 440-448. Go to original source...
  9. Mentha G, Roth AD, Terraz S, et al., ,Liver first" approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg 2008; 25: 430-435. Go to original source... Go to PubMed...
  10. Nordlinger B, Skrbte H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastase from colorectal cancor (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016. Go to original source... Go to PubMed...
  11. Chuas TC, Saxena A, Liauw W, et al. Systematic review of randomized and nonrandomized trial sof the clinical response and outcomes of neoadjuvant systemic chemotherapyx for resectable colorectal livcer metastases. Ann Surg Oncol 2010; 17: 492-501. Go to original source... Go to PubMed...
  12. Nordlinger B, et al. Combination of surgery nad chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastase: recommendation from an exper panel. Ann Oncol 2009; 20: 985-992. Go to original source... Go to PubMed...
  13. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Program and abstracts of the American Society of Clinical Oncology Annual Meeting 2007: abstr. 4000. Go to original source...
  14. Zorzi d, Kishi Y, Maru DM, et al. Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal liver metastase. 2009 Gastrointestinal Cancers Symposium, abstr. 295.
  15. Adam R, Lucidi V, Bismuth H. Hepatic colorectal metastases: methods of improving resectability. Surg Clin North Am 2004; 84: 659-671. Go to original source... Go to PubMed...
  16. Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy - missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14: 3188-3194. Go to original source... Go to PubMed...
  17. Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal vein embolization for major liver resection: a metaanalysis. Ann Surg 2008; 247: 49-57. Go to original source... Go to PubMed...
  18. de Graaf W, van Lienden KP, van den Esschert JW, et al. Increase in future remnant liver function after preoperative portal vein embolization. Br J Surg 2011; 98: 825-834. Go to original source... Go to PubMed...
  19. Kopetz S, Chang GJ, Overman MJ, et al. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 2009; 27: 3677-3683. Go to original source... Go to PubMed...
  20. Ryska M, Pantoflíček J, Dušek L. Léčba jaterních metastáz kolorektálního původu v České republice: současný celostátní survey. Rozhl Chir 2010; 89: 100-108. Go to PubMed...
  21. Klinický standard č. KKCCS0009 pro diagnostiku a léčbu pacientů se sekundárním zhoubným onemocněním jater, především u KRK. NRC 2011 (www.chirurgie.cz).




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.